This graphic shows the many types of Vaccines undergoing research, categorized by the immune response they are designed to elicit—broadly neutralizing antibodies, non-neutralizing antibodies, T-cell responses or a combination of these.
Vaccines Research Pipeline
AVAC’s “3D” View of the World: 2019 and beyond
This infographic lays out AVAC’s top-line recommendations from AVAC Report 2019: Now What? The recommendations fall into three categories: deliver — prevention programs whose impact is well-measured and -defined; demonstrate — next-generation engagement for next-generation trials; develop — new targets for the post-2020 world.
HIV Vaccine Research and Development Pipeline: 2019 Supplement
A slide deck overview of what’s happening in HIV vaccine research now.
Vaccine Strategies in the Pipeline
Scientists are studying these strategies to develop an effective vaccines and deliver it into the body in a way that maximizes the immune response.
HIV-Specific Neutralizing Antibodies – Targets and research status
Numerous studies, both early and late phase, are investigating the efficacy of neutralizing antibodies. This infographic shows the ongoing studies and the differing locations they target on the virus.
Vaccines Trial Participation in 2019
A look at the number of participants in vaccines trials in 2019 according to trial phase.
One Timeline, Two Stories, One Message: Putting trials and targets together
One problem with HIV prevention agendas is that they either live in an eternal present or in a far-off future. It’s “work with what we’ve got, which is condoms and VMMC and a little bit of PrEP”, or it’s “nothing can change without an AIDS vaccine”. The future depends on using what’s available, better and more widely, without ever losing sight of what’s in the pipeline.
As the figures below show, in the very same timeframe that the world will miss its critical target for incidence reduction and scale-up of primary prevention, several trials will release results that could change the future. 2020 will be a time of hope and reckoning. But only if the two stories start to be told as one.
HIV Prevention Research and Demonstration Sites in South Africa
This map demonstrates the breadth of HIV prevention research and demonstration projects in South Africa by site and type (e.g. daily oral PrEP demo projects, ARV-based rings, long-acting injectable PrEP, preventative Vaccines, antibodies, hormonal contraceptives). This map was developed by Wits RHI with support from AVAC as part of the Coalition to Accelerate and Support Prevention Research. This graphic first appeared in AVAC Report 2017: Mixed messages and how to untangle them.
Global HIV Prevention R&D Investment by Technology Category, 2000-2017
In 2017, reported funding for HIV prevention R&D decreased by 3.5 percent (US$40 million) from the previous year, falling to US$1.13 billion. The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download. And all the graphics are available as well.
HIV Prevention R&D Trial Participants by Region in 2017
Participation of volunteers and the engagement of communities in which trials take place is essential to conducting HIV prevention research. In 2017, there were nearly 600,000 participants in HIV prevention research trials globally, mostly originating from sub-Saharan Africa, Europe, North America and Asia. A majority of participants were enrolled in research investigating TasP and PrEP, and while there are trials aimed specifically at men who have sex with men (MSM), transgender individuals and people who inject drugs, most of the studies do not specify the need to include members of key populations.
The full report, HIV Prevention Research & Development Investments 2017: Investing to end the epidemic, is available for download.